Related Experiment Videos
[Felbamate: a long-term study in subjects with refractory epilepsy]
1Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma.
La Clinica Terapeutica
|March 1, 1997
Summary
Felbamate monotherapy offers significant seizure control for patients with refractory epilepsy. This new antiepileptic drug (AED) demonstrates effectiveness with manageable side effects, allowing long-term treatment.
Area of Science:
- Neurology
- Pharmacology
Background:
- Refractory epilepsy poses a significant challenge in patient management.
- Limited treatment options exist for complex partial seizures resistant to common antiepileptic drugs (AEDs).
Purpose of the Study:
- To evaluate the efficacy and safety of felbamate monotherapy in patients with refractory complex partial seizures.
- To compare felbamate's effectiveness against carbamazepine (CBZ) therapy.
Main Methods:
- An open-label study involving 18 patients with refractory epilepsy.
- Patients were treated with felbamate monotherapy for a 22-month period.
Main Results:
- Felbamate monotherapy showed a statistically significant improvement in seizure control compared to carbamazepine (CBZ) therapy.
- No severe adverse events, such as aplastic anemia or hepatic failure, were reported.
- All patients continued felbamate treatment after two years.
Conclusions:
- Felbamate is an effective new antiepileptic drug (AED).
- Common adverse effects include mild to moderate gastrointestinal and central nervous system disturbances.
- These side effects are generally transient (lasting ~3 weeks) and permit continued treatment.